multiple myeloma
FDA Grants Accelerated Approval to Lynozyfic for Relapsed or Refractory Multiple Myeloma
The FDA granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron), a bispecific B-cell maturation ...
JULY 2, 2025
Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma
Amneal Pharmaceuticals Inc. and Shilpa Medicare Limited announced the U.S. launch of Boruzu, a new presentation of ...
APRIL 8, 2025
Amneal Receives FDA Approval for Lenalidomide
Amneal Pharmaceuticals Inc. has received approval from the FDA for its Abbreviated New Drug Application for ...
MARCH 5, 2025
Daratumumab Delays Transition From Smoldering to Active Multiple Myeloma
In a phase 3 trial, the anti-38 monoclonal antibody daratumumab (Darzalex, Johnson & Johnson) substantially ...
FEBRUARY 19, 2025
Harnessing the Potential of CAR T-Cell Therapy for Multiple Myeloma
Multiple myeloma, a blood cancer that develops in plasma cells, can result in low blood counts and weakening of the ...
FEBRUARY 3, 2025
FDA Approves Sarclisa With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
The FDA has approved isatuximab-irfc (Sarclisa, Sanofi-Aventis) with bortezomib, lenalidomide and dexamethasone for ...
SEPTEMBER 23, 2024
FDA Approves Darzalex Faspro With Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development LLC) ...
JULY 31, 2024
Latest DREAMM Trial Suggests Potential Standard for Relapsed Multiple Myeloma
The most recent in a series of trials of multiple-drug combinations with the antibody-drug conjugate belantamab ...
JUNE 19, 2024
FDA Approves New Indication for Abecma in Multiple Myeloma
The FDA approved idecabtagene vicleucel (ide-cel) (Abecma, Bristol Myers Squibb/2seventy bio) for the treatment of ...
APRIL 10, 2024
FDA Approves First Interchangeable Biosimilars to Xgeva and Prolia
The FDA approved the first interchangeable biosimilar to Prolia (denosumab) and Xgeva (denosumab). Sandoz’s ...
MARCH 6, 2024
FDA Issues Final Decision to Withdraw Approval of Pepaxto for Multiple Myeloma
The FDA has announced its final decision to withdraw approval of melphalan flufenamide (Pepaxto, Oncopeptides), ...
FEBRUARY 26, 2024
Compared With Standard Multiple Myeloma Therapy, Isatuximab Doubles Odds of MRD Negativity
In transplant-eligible patients with newly diagnosed multiple myeloma (MM), the novel anti-CD38 monoclonal antibody ...
FEBRUARY 23, 2024